Ubs Asset Management Americas Inc Biocryst Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 394,740 shares of BCRX stock, worth $2.79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
394,740
Previous 691,969
42.95%
Holding current value
$2.79 Million
Previous $6.2 Million
51.68%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding BCRX
# of Institutions
311Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY12.2MShares$86.2 Million1.72% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...